Organon & Co. (OGN) Competitors $9.22 +0.11 (+1.21%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$9.23 +0.01 (+0.11%) As of 08/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OGN vs. BBIO, VRNA, BPMC, ROIV, GRFS, LEGN, ELAN, RVMD, RGC, and RYTMShould you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Regencell Bioscience (RGC), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Organon & Co. vs. Its Competitors BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Grifols Legend Biotech Elanco Animal Health Revolution Medicines Regencell Bioscience Rhythm Pharmaceuticals Organon & Co. (NYSE:OGN) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership. Do insiders & institutionals have more ownership in OGN or BBIO? 77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 2.0% of Organon & Co. shares are owned by company insiders. Comparatively, 18.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor OGN or BBIO? In the previous week, BridgeBio Pharma had 12 more articles in the media than Organon & Co.. MarketBeat recorded 33 mentions for BridgeBio Pharma and 21 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.53 beat BridgeBio Pharma's score of 0.49 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 4 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive BridgeBio Pharma 10 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation and earnings, OGN or BBIO? Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.40B0.37$864M$2.693.43BridgeBio Pharma$221.90M40.13-$535.76M-$4.09-11.39 Do analysts prefer OGN or BBIO? Organon & Co. currently has a consensus price target of $18.00, indicating a potential upside of 95.23%. BridgeBio Pharma has a consensus price target of $61.35, indicating a potential upside of 31.72%. Given Organon & Co.'s higher possible upside, analysts clearly believe Organon & Co. is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, OGN or BBIO? Organon & Co. has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Is OGN or BBIO more profitable? Organon & Co. has a net margin of 11.15% compared to BridgeBio Pharma's net margin of -329.25%. Organon & Co.'s return on equity of 163.88% beat BridgeBio Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.11.15% 163.88% 6.99% BridgeBio Pharma -329.25%N/A -85.69% SummaryOrganon & Co. beats BridgeBio Pharma on 10 of the 17 factors compared between the two stocks. Get Organon & Co. News Delivered to You Automatically Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGN vs. The Competition Export to ExcelMetricOrganon & Co.Medical Services IndustryMedical SectorNYSE ExchangeMarket Cap$2.40B$7.33B$5.52B$20.75BDividend Yield0.87%2.75%4.60%3.66%P/E Ratio3.4365.5630.0128.05Price / Sales0.3730.87450.0556.30Price / Cash1.8725.7836.7723.05Price / Book3.2717.878.184.33Net Income$864M$243.10M$3.26B$994.32M7 Day Performance-5.53%2.42%6.13%1.97%1 Month Performance-8.08%-4.08%0.07%-1.60%1 Year Performance-54.24%18.47%36.31%14.39% Organon & Co. Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGNOrganon & Co.4.7542 of 5 stars$9.22+1.2%$18.00+95.2%-54.2%$2.40B$6.40B3.434,000Earnings ReportDividend AnnouncementBBIOBridgeBio Pharma4.7237 of 5 stars$47.75+0.8%$61.18+28.1%+90.7%$9.07B$127.42M-13.53400Trending NewsEarnings ReportAnalyst ForecastInsider TradeOptions VolumeAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share1.5579 of 5 stars$105.47+0.3%$109.00+3.3%+365.4%$8.55B$118.54M-52.7430Positive NewsEarnings ReportInsider TradeBPMCBlueprint Medicines0.6453 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences2.1503 of 5 stars$11.51+1.8%$16.50+43.4%+3.3%$7.82B$29.05M-46.04860Positive NewsUpcoming EarningsGRFSGrifols3.3304 of 5 stars$10.72-0.6%$10.30-3.9%+47.9%$7.37B$7.81B9.1623,822Positive NewsAnalyst ForecastLEGNLegend Biotech3.8262 of 5 stars$38.45-0.9%$73.33+90.7%-33.8%$7.07B$728.30M-65.172,609News CoverageUpcoming EarningsAnalyst RevisionELANElanco Animal Health3.3371 of 5 stars$14.07+2.1%$16.17+14.9%+27.4%$6.99B$4.43B19.029,000Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionRVMDRevolution Medicines4.3424 of 5 stars$37.18+1.5%$68.91+85.3%-18.4%$6.93BN/A-9.30250News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionRGCRegencell Bioscience0.1884 of 5 stars$13.76+6.1%N/AN/A$6.80BN/A0.0010RYTMRhythm Pharmaceuticals3.9966 of 5 stars$90.24+2.2%$91.93+1.9%+103.2%$5.74B$136.86M-32.11140Earnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies BBIO Alternatives VRNA Alternatives BPMC Alternatives ROIV Alternatives GRFS Alternatives LEGN Alternatives ELAN Alternatives RVMD Alternatives RGC Alternatives RYTM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGN) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
